PHN

Acasti Pharma Awarded Composition-of-Matter Patents for GTX-101 in Europe, China and Mexico and for GTX-102 in Japan

Retrieved on: 
수요일, 10월 6, 2021
ACST, PHN, Betamethasone, European Patent Convention, Physical disability, Securities Act of 1933, Subarachnoid hemorrhage, Patent, Compliance, Orphan, PK, Risk, Security (finance), TSX, Drug Quality and Security Act, Skull, Postherpetic neuralgia, NASDAQ, U.S. Securities and Exchange Commission, FDA, Nerve Damage, A-T, SubArachnoid Space, Marketing, GLOBE, Bupivacaine, Disability, Private Securities Litigation Reform Act, SAH, Lists of diseases, COVID-19, Bleeding, Brain, Neuropathic pain, Safety, China National Intellectual Property Administration, Securities Exchange Act of 1934, Opposition procedure before the European Patent Office, Pharmaceutical industry

GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief.

Key Points: 
  • GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief.
  • A-T is a progressive, neurodegenerative genetic disease that primarily affects children causing severe physical disability, for which no treatment currently exists.
  • We believe these granted composition of matter patents further support the commercial potential of GTX-101 and GTX-102.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

Acasti Pharma Announces Initiation of Pharmacokinetic Bridging Study for GTX-104, the Company’s Lead Drug Candidate for the Treatment of Subarachnoid Hemorrhage

Retrieved on: 
월요일, 9월 27, 2021
ACST, Securities Act of 1933, Review, Death, Stroke, Micelle, Bleeding, Safety, Calendar, Blood pressure, Subarachnoid hemorrhage, Compliance, Drug Quality and Security Act, CRU, IV, Central nervous system, SubArachnoid Space, Private Securities Litigation Reform Act, Disability, BA, SAH, Capsule, Incidence, Brain, Orphan, Aneurysm, Water, NASDAQ, U.S. Securities and Exchange Commission, FDA, Nimodipine, Experimental cancer treatment, A-T, Marketing, Acquisition, Company, Vital signs, DCI, GLOBE, PHN, Grace, PK, Risk, TSX, Security (finance), Skull, Postherpetic neuralgia, Patient, Nerve Damage, Rupture, COVID-19, Securities Exchange Act of 1934, Neuropathic pain, Blood, ASAH, Cryptocurrency, Pharmaceutical industry, Medical imaging

This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.

Key Points: 
  • This latest study follows an earlier safety and dose-escalation crossover study conducted by Grace, which reported encouraging results.
  • Moreover, it could provide a more convenient dosing schedule that would be easier to administer to patients who are unconscious.
  • The PK bridging study is a single center, randomized, two-period crossover study in 50 healthy subjects.
  • Acasti is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases.

The Passive House Network Announces Call for Papers & Ideas for 2022 National Passive House Conference

Retrieved on: 
수요일, 9월 22, 2021
Adoption, PHN, Ventilation, Housing association, Policy, National Conference, Indian, Conference, Heat, Hospital, PHI, Public policy, Public health, Bright House Networks, Creativity, Passive house, Imagination, Industry, Management, Risk management, Interior design, Communications satellite, Heating, ventilation, and air conditioning

NEW YORK, Sept. 22, 2021 /PRNewswire-PRWeb/ -- The Passive House Network (PHN), formerly NAPHN, announced today the call for papers and ideas for its 2022 National Conference.

Key Points: 
  • NEW YORK, Sept. 22, 2021 /PRNewswire-PRWeb/ -- The Passive House Network (PHN), formerly NAPHN, announced today the call for papers and ideas for its 2022 National Conference.
  • "The region is a long-time leader in sustainable building and continues today in its support of Passive House.
  • Find our more: http://www.phnconference.org
    About The Passive House Network:
    The Passive House Network (PHN), formerly known as NAPHN, is a high-performance building literacy program.
  • PHN is an independent national non-profit educational organization affiliated with the International Passive House Association (iPHA) and the Passive House Institute (PHI), located in Darmstadt, Germany.

Acasti Pharma Provides Update Following Acquisition of Grace Therapeutics and Regains Compliance with Nasdaq Listing Standards

Retrieved on: 
수요일, 9월 22, 2021
ACST, PHN, Securities Act of 1933, Subarachnoid hemorrhage, Review, Compliance, Risk, TSX, Skull, Postherpetic neuralgia, NASDAQ, FDA, A-T, Nerve Damage, SubArachnoid Space, Marketing, Private Securities Litigation Reform Act, Disability, Company, SAH, COVID-19, Bleeding, Brain, Neuropathic pain, Securities Exchange Act of 1934, SEC, GLOBE, Pharmaceutical industry

Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, commented, We are pleased to have regained compliance with the listing requirements for Nasdaq, and are laser focused on the integration of Grace Therapeutics, which is progressing seamlessly.

Key Points: 
  • Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, commented, We are pleased to have regained compliance with the listing requirements for Nasdaq, and are laser focused on the integration of Grace Therapeutics, which is progressing seamlessly.
  • Specifically, these drug candidates are designed to achieve faster onset of action, enhanced efficacy, reduced side effects, and more convenient drug delivery.
  • Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.
  • Acasti undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

The Passive House Network Announces Launch of Introduction to Passive House Trades Course

Retrieved on: 
월요일, 9월 20, 2021
Adoption, PHN, Ventilation, Ross House Association, Climate, Health, Indian, AIA, Heat, Associate, Hospital, PHI, Bright House Networks, Introduction, Passive house, Industry, Construction, Interior design, Communications satellite, Heating, ventilation, and air conditioning

NEW YORK, Sept. 20, 2021 /PRNewswire-PRWeb/ -- The Passive House Network (PHN) announced today the launch of the Introduction to Passive House Trades course, as a half day live-online training for contractors and tradespeople working on Passive House residential and commercial building construction.

Key Points: 
  • NEW YORK, Sept. 20, 2021 /PRNewswire-PRWeb/ -- The Passive House Network (PHN) announced today the launch of the Introduction to Passive House Trades course, as a half day live-online training for contractors and tradespeople working on Passive House residential and commercial building construction.
  • The first Introduction to Passive House Trades course will run October 13, from 1 to 5 PM ET.
  • This course can be accessed at: https://naphnetwork.org/education/introductory/intro-to-trades/
    About The Passive House Network:
    The Passive House Network (PHN), formerly known as NAPHN, is a high-performance building literacy program.
  • PHN is an independent national non-profit educational organization affiliated with the International Passive House Association (iPHA) and the Passive House Institute (PHI), located in Darmstadt, Germany.

Acasti Pharma to Present at the Oppenheimer Fall Healthcare Summit on September 21ˢᵗ

Retrieved on: 
화요일, 9월 14, 2021
Neuropathic pain, Oppenheimer, Medtech, FDA, PHN, Marketing, Postherpetic neuralgia, Bleeding, A-T, ACST, Disability, RSVP, NASDAQ, Skull, Subarachnoid hemorrhage, Brain, SubArachnoid Space, GLOBE, Compliance, Finance, TSX, SAH, Nerve Damage, Pharmaceutical industry

LAVAL, Qubec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.

Key Points: 
  • LAVAL, Qubec, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Acasti or the Company) (Nasdaq: ACST and TSX-V: ACST), today announced that it will be presenting at the Oppenheimer Fall Healthcare Summit being held virtually September 20-23, 2021.
  • Jan DAlvise, President and Chief Executive Officer of Acasti Pharma, is scheduled to present on Tuesday, September 21, 2021 at 2:05 PM Eastern Time.
  • Oppenheimer Fall Healthcare Life Sciences & MedTech Summit will feature presentations and one-on-one meetings in a virtual format with a select group of public companies in the Healthcare Life Sciences and MedTech arena.
  • Acasti is a late-stage specialty pharma company with drug delivery capability and technologies addressing rare and orphan diseases.

The Passive House Network Announces Launch of Passive House Planning Package (PHPP) Course

Retrieved on: 
금요일, 9월 10, 2021

NEW YORK, Sept. 10, 2021 /PRNewswire-PRWeb/ --The Passive House Network announced today the launch of the Passive House Planning Package (PHPP) course as an online, on-demand, training for Passive House home design and construction.

Key Points: 
  • NEW YORK, Sept. 10, 2021 /PRNewswire-PRWeb/ --The Passive House Network announced today the launch of the Passive House Planning Package (PHPP) course as an online, on-demand, training for Passive House home design and construction.
  • Founder, Andrew Peel stated, "We are excited to help offer this course to Passive House practitioners across the US and North America because understanding and working with the PHPP is essential to making effective Passive House buildings."
  • This course can be accessed at: https://naphnetwork.org/education/specialized/phpp/
    About The Passive House Network:
    The Passive House Network (PHN), formerly know as NAPHN, is a high-performance building literacy program.
  • PHN is an independent national non-profit educational organization affiliated with the International Passive House Association (iPHA) and the Passive House Institute (PHI), located in Darmstadt, Germany.

Acasti Pharma Announces Successful Completion of its Merger with Grace Therapeutics, Inc., Voting Results of its Annual and Special Meeting of Shareholders and Reverse Stock Split

Retrieved on: 
금요일, 8월 27, 2021
Company, Postherpetic neuralgia, Nerve Damage, Hoskin, LLC, Securities Exchange Act of 1934, PHN, KPMG LLP, Securities Act of 1933, Osler, Hoskin & Harcourt, Skull, GLOBE, Acquisition, SEC, William Blair & Company, Board of directors, Research, SubArachnoid Space, Disability, Neuropathic pain, Private Securities Litigation Reform Act, LLP, Marketing, Oppenheimer Holdings, AGSM, Intellectual property, ACST, Review, Risk, Board, Bleeding, NASDAQ, KPMG, Compliance, Subarachnoid hemorrhage, Circular, FDA, Remuneration, Brain, COVID-19, A-T, SAH, Pharmaceutical industry, Holding company, Security (finance)

The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases.

Key Points: 
  • The successful completion of the merger positions Acasti to build a premier, late-stage specialty pharma company focused on rare diseases.
  • We believe the Grace acquisition will be truly transformative, creating new and exciting opportunities for us in sizable markets with substantial unmet medical needs.
  • In connection with the transaction, Grace was merged with a new wholly owned subsidiary of Acasti and became a subsidiary of Acasti.
  • At the AGSM, shareholders approved the issuance of Acasti shares as consideration to Grace securityholders pursuant to the merger.